Lotus Pharmaceutical Co Ltd (1795 TW) stock market data APIs
NT$173.8144
3.53(2%)
as of October 22, 2026
Try our APIs with
free plan!
Lotus Pharmaceutical Co Ltd Financial Data Overview
Price chart is built with
Anychart
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
Prev. Close
173.8144
Open
177.3398
High
177.7555
Low
172.6931
52 wk Range
170.5-369.5
Market Cap
45 961 M
P/E Ratio
12.1308
Shares Outstanding
266 M
Revenue
28 486 M
EPS
2.43
Dividends (Yield)
0.0144
Beta
0.657
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lotus Pharmaceutical Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lotus Pharmaceutical Co Ltd data using free add-ons & libraries
Get Lotus Pharmaceutical Co Ltd Fundamental Data
Lotus Pharmaceutical Co Ltd Fundamental data includes:
- Net Revenue: 28 486 M
- EBITDA: 9 202 M
- Earnings Per Share: 14
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Lotus Pharmaceutical Co Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: 2.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lotus Pharmaceutical Co Ltd News
New
Why Lotus Pharmaceutical Fell Even As Sales Rose
Lotus Pharmaceutical reported higher revenue but slimmer profits in its latest results, which can feel like the kind of progress investors usually welcome. Holding Lotus Pharmaceutical over the past y...
Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?
Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Ov...
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical
In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eig...
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Alvotech REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patient...
Get Lotus Pharmaceutical Co Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.